375 related articles for article (PubMed ID: 11889082)
41. Angiogenesis and portal-systemic collaterals in portal hypertension.
Gana JC; Serrano CA; Ling SC
Ann Hepatol; 2016; 15(3):303-13. PubMed ID: 27049484
[TBL] [Abstract][Full Text] [Related]
42. The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats.
Distrutti E; Mencarelli A; Santucci L; Renga B; Orlandi S; Donini A; Shah V; Fiorucci S
Hepatology; 2008 Feb; 47(2):659-67. PubMed ID: 18098324
[TBL] [Abstract][Full Text] [Related]
43. The effect of mechanically enhancing portal venous inflow on hepatic oxygenation, microcirculation, and function in a rabbit model with extensive hepatic fibrosis.
Jiao LR; Seifalian AM; Habib N; Davidson BR
Hepatology; 1999 Jul; 30(1):46-52. PubMed ID: 10385637
[TBL] [Abstract][Full Text] [Related]
44. Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability.
Lee KC; Yang YY; Huang YT; Lee FY; Hou MC; Lin HC; Lee SD
Clin Sci (Lond); 2010 Apr; 119(1):45-55. PubMed ID: 20132096
[TBL] [Abstract][Full Text] [Related]
45. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
[TBL] [Abstract][Full Text] [Related]
46. The hepatic circulation in health and disease: report of a single-topic symposium.
Shah V; García-Cardeña G; Sessa WC; Groszmann RJ
Hepatology; 1998 Jan; 27(1):279-88. PubMed ID: 9425948
[No Abstract] [Full Text] [Related]
47. Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.
Garbuzenko DV
World J Gastroenterol; 2015 May; 21(20):6117-26. PubMed ID: 26034348
[TBL] [Abstract][Full Text] [Related]
48. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension.
Tripathi DM; Vilaseca M; Lafoz E; Garcia-Calderó H; Viegas Haute G; Fernández-Iglesias A; Rodrigues de Oliveira J; García-Pagán JC; Bosch J; Gracia-Sancho J
Gastroenterology; 2018 Nov; 155(5):1564-1577. PubMed ID: 30055171
[TBL] [Abstract][Full Text] [Related]
49. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide.
Rockey D
Hepatology; 1997 Jan; 25(1):2-5. PubMed ID: 8985256
[No Abstract] [Full Text] [Related]
50. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?
Thabut D; Shah V
J Hepatol; 2010 Nov; 53(5):976-80. PubMed ID: 20800926
[TBL] [Abstract][Full Text] [Related]
51. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome.
Testro AG; Angus PW
J Gastroenterol Hepatol; 2009 Nov; 24(11):1707-9. PubMed ID: 20136956
[No Abstract] [Full Text] [Related]
52. Alteration of intrahepatic microcirculation in cirrhotic livers.
Yang YY; Lin HC
J Chin Med Assoc; 2015 Aug; 78(8):430-7. PubMed ID: 26074366
[TBL] [Abstract][Full Text] [Related]
53. Kupffer cell depletion attenuates leptin-mediated methoxamine-stimulated portal perfusion pressure and thromboxane A2 release in a rodent model of NASH-cirrhosis.
Yang YY; Huang YT; Tsai TH; Hou MC; Lee FY; Lee SD; Lin HC
Clin Sci (Lond); 2012 Dec; 123(12):669-80. PubMed ID: 22734967
[TBL] [Abstract][Full Text] [Related]
54. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
[TBL] [Abstract][Full Text] [Related]
55. Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents.
Kageyama Y; Ikeda H; Watanabe N; Nagamine M; Kusumoto Y; Yashiro M; Satoh Y; Shimosawa T; Shinozaki K; Tomiya T; Inoue Y; Nishikawa T; Ohtomo N; Tanoue Y; Yokota H; Koyama T; Ishimaru K; Okamoto Y; Takuwa Y; Koike K; Yatomi Y
Hepatology; 2012 Oct; 56(4):1427-38. PubMed ID: 22505286
[TBL] [Abstract][Full Text] [Related]
56. Emerging therapies for portal hypertension in cirrhosis.
Nair H; Berzigotti A; Bosch J
Expert Opin Emerg Drugs; 2016 Jun; 21(2):167-81. PubMed ID: 27148904
[TBL] [Abstract][Full Text] [Related]
57. Antiangiogenic therapies in portal hypertension: a breakthrough in hepatology.
Rosmorduc O
Gastroenterol Clin Biol; 2010 Sep; 34(8-9):446-9. PubMed ID: 20630674
[TBL] [Abstract][Full Text] [Related]
58. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis.
Møller S; Bendtsen F
Liver Int; 2018 Apr; 38(4):570-580. PubMed ID: 28921803
[TBL] [Abstract][Full Text] [Related]
59. Hepatic microcirculatory disturbance in fatty liver as a cause of portal hypertension.
Yoshihara H; Hijioka T; Eguchi H; Fukui H; Goto M; Inoue A; Kawano S; Sato N; Kamada T
J Gastroenterol Hepatol; 1989; 4 Suppl 1():279-81. PubMed ID: 2519076
[No Abstract] [Full Text] [Related]
60. Regulatory mechanisms of hepatic microcirculatory hemodynamics: hepatic arterial system.
Oda M; Yokomori H; Han JY
Clin Hemorheol Microcirc; 2006; 34(1-2):11-26. PubMed ID: 16543613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
